Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 11Breast Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 8Carcinoma, Merkel Cell 8Neoplasms 7Colorectal Neoplasms 7Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Neuroendocrine 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Sarcoma 2Penile Neoplasms 2Pancreatic Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm, Residual 2Mesothelioma, Malignant 2

Interventions

fludarabine phosphate 26Etoposide 23Peripheral Blood Stem Cell Transplantation 22pegaspargase 21Whole-Body Irradiation 21Mycophenolic Acid 20Cyclophosphamide 19Busulfan 17Gemcitabine 16Dexamethasone 16Tacrolimus 15Methotrexate 15Cyclosporine 12Radiotherapy 11Antilymphocyte Serum 11Melphalan 8Asparaginase 8Rituximab 7Oxaliplatin 7Flow Cytometry 6Therapeutics 5Lenalidomide 5Bortezomib 5thymoglobulin 4spartalizumab 4Transplantation 4Polymerase Chain Reaction 4Panobinostat 4Methylprednisolone 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Extranodal NK-T-Cell × avelumab × Clear all
NCT03439501 2021-09-24

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Samsung Medical Center

Phase 2 Unknown
21 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡